Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common stock issued for cash at $5.86	Common stock issued for cash at $18.95	Preferred stock issued for cash at $1,000 per share	Common Stock Issued to Galloway	Common stock issued for cash at $5.90 per share	Novartis	Amgen	Preferred Stock	Preferred Stock Preferred stock issued for cash at $1,000 per share	Common Stock	Common Stock Common stock issued for cash at $5.86	Common Stock Common stock issued for cash at $18.95	Common Stock Common Stock Issued to Galloway	Common Stock Common stock issued for cash at $5.90 per share	Common Stock Novartis	Common Stock Amgen	Additional Paid In Capital	Additional Paid In Capital Common stock issued for cash at $5.86	Additional Paid In Capital Common stock issued for cash at $18.95	Additional Paid In Capital Preferred stock issued for cash at $1,000 per share	Additional Paid In Capital Common Stock Issued to Galloway	Additional Paid In Capital Common stock issued for cash at $5.90 per share	Additional Paid In Capital Novartis	Additional Paid In Capital Amgen	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit	Noncontrolling Interest
Beginning Balance, Amount at Sep. 30, 2013	$ 25,734,789								$ 10		$ 124,859							$ 193,514,766									$ (166,140,969)	$ (1,763,877)
Beginning Balance, Shares at Sep. 30, 2013									9,900		32,489,444
Exercise of warrants, Amount	10,148,044										$ 2,911							10,145,133
Exercise of warrants, Shares											2,911,919
Exercise of stock options, Amount	2,730,000										$ 455							2,729,545
Exercise of stock options, Shares											454,863
Stock-based compensation	5,696,173																	5,696,173
Stock issuances		$ 14,060,112	$ 112,581,559	$ 46,000,000	$ 500,000					$ 46		$ 3,072	$ 6,325	$ 132					$ 14,057,040	$ 112,575,234	$ 45,999,954	$ 499,868
Stock issuances, Shares										46,000		3,071,672	6,325,000	131,579
Settlements related to derivative liability	5,956,079																	5,956,079
Preferred stock converted to common stock, Amount									$ (38)		$ 9,272							(9,234)
Preferred stock converted to common stock, Shares									(37,600)		9,272,459
Deconsolidation of Calando Pharmaceuticals, Inc.	1,303,911																											1,303,911
Net loss	(58,725,412)																										(58,630,190)	(95,222)
Ending Balance, Amount at Sep. 30, 2014	165,985,255								$ 18		$ 147,026							391,164,558									(224,771,159)	(555,188)
Ending Balance, Shares at Sep. 30, 2014									18,300		54,656,936
Exercise of warrants, Amount	401,876										$ 81							401,795
Exercise of warrants, Shares											79,828
Exercise of stock options, Amount	101,870										$ 29							101,841
Exercise of stock options, Shares											28,758
Stock-based compensation	10,232,897																	10,232,897
Exercise of exchange rights, Amount	3,072										$ 5							3,067
Exercise of exchange rights, Shares											5,250
Preferred stock converted to common stock, Amount									$ (2)		$ 1,316							(1,314)
Preferred stock converted to common stock, Shares									(2,648)		1,316,215
Common stock- Restricted Stock Units vesting, Amount	(26,029)										$ 136							(26,165)
Common stock- Restricted Stock Units vesting, Shares											136,307
Stock issuances							$ 25,000,000									$ 3,321								$ 24,996,679
Stock issuances, Shares																3,321,383
Foreign Currency Translation Adjustments	(136,425)																									$ (136,425)
Net loss	(91,940,882)																										(91,940,882)
Ending Balance, Amount at Sep. 30, 2015	109,621,634								$ 16		$ 151,914							426,873,358								(136,425)	(316,712,041)	(555,188)
Ending Balance, Shares at Sep. 30, 2015									15,652		59,544,677
Exercise of warrants, Amount	3,691,398										$ 853							3,690,545
Exercise of warrants, Shares											852,532
Exercise of stock options, Amount	$ 133,869										$ 37							133,832
Exercise of stock options, Shares	37,187										37,187
Stock-based compensation	$ 11,595,816																	11,595,816
Stock issuances						$ 43,231,435		$ 9,000,000							$ 7,627		$ 1,257						$ 43,223,808		$ 8,998,743
Stock issuances, Shares															7,627,119		1,256,983
Common stock- Restricted Stock Units vesting, Amount	(670,765)										$ 428							(671,193)
Common stock- Restricted Stock Units vesting, Shares											428,187
Foreign Currency Translation Adjustments	143,874																									143,874
Net loss	(81,723,002)																										(81,723,002)
Ending Balance, Amount at Sep. 30, 2016	$ 95,024,259								$ 16		$ 162,116							$ 493,844,909								$ 7,449	$ (398,435,043)	$ (555,188)
Ending Balance, Shares at Sep. 30, 2016									15,652		69,746,685